Workflow
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Core Insights - Ernexa Therapeutics has developed a novel iMSC-based immunotherapy platform that successfully converts "cold" ovarian tumors into "hot" tumors, potentially enhancing immune response and improving patient outcomes [1][2][4] Company Overview - Ernexa Therapeutics (Nasdaq: ERNA) focuses on innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5][6] - The company is currently developing two preclinical cell therapy products: ERNA-101, aimed at activating the immune system against cancer, and ERNA-102, targeting inflammation in autoimmune diseases [6] Research Findings - The study demonstrated that iMSCs engineered to secrete cytokines IL-7 and IL-15 can migrate into the tumor microenvironment, leading to significant immune activation, including T cell and macrophage infiltration [2][3] - In a syngeneic ovarian cancer mouse model, treatment with IL-7/IL-15-secreting iMSCs resulted in a significant reduction in tumor burden and extended survival [3] Upcoming Presentation - Ernexa will present its findings at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025, with a poster titled "Engineering iPSC-derived mesenchymal stem cells (iMSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a 'cold' ovarian tumor model" [4]